[Antitumor effect of epidermal growth factor receptor gene silencing]

Area of Science:

• Molecular Biology
• Cancer Research
• RNA Therapeutics

Background:

• Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
• Epidermal growth factor receptor (EGFR) is a key driver in NSCLC pathogenesis and a validated therapeutic target.
• Gene silencing strategies offer a promising avenue for novel NSCLC treatments.

Purpose of the Study:

• To evaluate the efficacy of chemically synthesized double-stranded RNA (dsRNA) targeting EGFR for gene silencing in NSCLC cells.
• To quantify the extent of EGFR gene and protein downregulation induced by dsRNA.
• To assess the functional impact of EGFR silencing on NSCLC cell proliferation and tumor growth in vivo.

Main Methods:

• NSCLC cell line SPC-A-1 was transfected with EGFR-specific dsRNA using Lipofectamine 2000.
• EGFR protein reduction was measured by fluorescent microscopy and flow cytometry.
• EGFR gene silencing was quantified using real-time PCR.
• In vitro cellular proliferation and colony formation were assessed via colony assay.
• In vivo tumor growth inhibition was evaluated in an athymic nude mouse model.

Main Results:

• dsRNA targeting EGFR achieved a 71.3% reduction in EGFR protein production and 50.0% gene silencing.
• In vitro, dsRNA-EGFR significantly decreased colony numbers by 66.8%.
• In vivo, dsRNA-EGFR demonstrated a 75.0% tumor growth inhibition rate.

Conclusions:

• Sequence-specific dsRNA targeting EGFR is highly effective in downregulating EGFR gene and protein expression.
• EGFR silencing via dsRNA significantly inhibits NSCLC cellular proliferation and tumor growth.
• This dsRNA-based approach holds substantial promise as a therapeutic strategy for NSCLC.